Bronchiectasis exacerbations in children: What predicts the response to antibiotics?

• Main Authors: Goyal, V, Marchant, J, Grimwood, K, Masters, B, Yerkovich, S, Chang, A
• Format: Conference Object
• Language: English
• Published: WILEY 2021
• Subjects: Biomedical and clinical sciences; Health sciences; Science & Technology; Life Sciences & Biomedicine; Respiratory System; First Nations
• Online Access: http://hdl.handle.net/10072/404616

Introduction/Aim: Respiratory exacerbations in children with bronchiectasis are treated with antibiotics. While oral antibiotics are superior to placebo and recommended by guidelines to treat children with non-severe (non-hospitalized) exacerbations, not all will benefit. Therefore, we aimed to identify factors predicting those who will improve after a 14-day oral antibiotic course. Methods: Demographic and clinical data from our two recently completed double-blind, double-dummy, randomized controlled trials were retrieved for the 202 children who received at least 14-days of oral antibiotics to treat their non-severe exacerbations. Univariable and multivariable logistic regression was used to identify factors associated with their response to antibiotics. Results: Of the 202 children (51% males), 41% were Indigenous (Maori or Australian First Nations). Their median age was 4.2 (interquartile range 2.3–6.7) years at diagnosis of bronchiectasis. All received 14-days of amoxicillin-clavulanate or azithromycin. By Day-14, 130 (64%) children had improved according to validated cough score and clinical assessments, while 72 had not. Baseline characteristics were similar in both responder and non-responder groups. Univariable analysis found significant differences between groups for Indigenous ethnicity, number of non-hospitalized exacerbations needing antibiotics in the preceding 2-years, and number of lobes affected by bronchiectasis. Following multivariable analysis, Indigenous ethnicity (ORadjusted=4.70 95%CI 2.20–10.01), cough score at the exacerbation beginning (ORadjusted=0.58 95%CI 0.39–0.86) and number of lobes affected by bronchiectasis (ORadjusted=0.75 95%CI 0.57–0.99) were significant factors in identifying responders. Detecting a respiratory virus at the beginning of an exacerbation did not affect the response to antibiotics. Conclusion: Among children with a non-severe bronchiectasis exacerbation, those more likely to respond to oral antibiotics were of Indigenous background, had less severe ...